Availability More Than Strategy Driving Takeda's Shire Interest?
While Takeda has admitted it is considering a possible offer for Shire, any deal would seem to go against some of the past strategy signals from the Japanese company, suggesting the availability of an increasingly rare acquisition target may be more of a key consideration.
You may also be interested in...
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.
Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid
Takeda's most recent offer for Shire had an estimated total value of $61bn, but likely included too much equity and too little cash. The companies continue negotiating as an April 25 deadline looms, while Allergan stated it won't bid for Shire.